GLUCOTAB- TABLET

Presentation

GLUCOTAB-Tablets: White, scored, oblong tablets, engraved with ‘GLUCOTAB; each tablet contains 5gm glibenclamide BP.

Uses

GLUCOTAB is an oral hypoglycaemic agent of the sulphonylurea type. GLUCOTAB is indicated for the treatment of non-insulin dependent diabetes which is not adequately controlled by dietary measures alone.

Dosage and administration

GLUCOTAB should be taken with or immediately after food. The total daily dosage is preferably given as a single dose at breakfast or with the first main meal. but due consideration should be given to the patient’s meal habits and daily activity when apportioning dosage.

New diabetics: In maturity-onset diabetes of mild to moderate severity, treatment should be started with 5 mg daily of 2.5mg in debilitated or elderly patients. If this dosage is not sufficient for proper control it should be increased by 2.5mg at intervals of one week, or as directed by the clinician. The total daily dose of GLUCOTAB should not exceed 15mg. Increasing dosage beyond this level is unlikely to produce further response.

Transfer from other sulphonylureas: Transfer to GLUCOTAB can e usually by carried out without any break in therapy. GLUCOTAB treatment should be started with 5 mg daily and , if necessary, adjusted in steps of 2.5 or 5 mg. dosage is 1 to 2 tablets every 3 or 4 hours with a maximum of 8 tablets in 24 hours.

Changeover from biguanides: GLUCOTAB treatment should be started with 2.5 mg of GLUCOTAB and the biguanide withdrawn. Dosage should then be adjusted by increments of 2.5 mg to achieve control.